Evidence map›Paper›PMID 38328479›Full record

ArticleJournal of the Endocrine Society2024

Phenotype of Parathyroid-targeted

Jessica Costa-Guda, Sarah T Cohen, Robert Romano, Jennifer Acostamadiedo, Kevin Clark, Justin Bellizzi, Andrew Arnold

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the Endocrine Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jessica Costa-GudaCenter for Molecular Oncology, University of Connecticut School of Medicine, Farmington, CT 06030-3101, USA.ORCID https://orcid.org/0000-0001-6437-1693
Sarah T CohenCenter for Molecular Oncology, University of Connecticut School of Medicine, Farmington, CT 06030-3101, USA.
Robert RomanoCenter for Molecular Oncology, University of Connecticut School of Medicine, Farmington, CT 06030-3101, USA.
Jennifer AcostamadiedoCenter for Molecular Oncology, University of Connecticut School of Medicine, Farmington, CT 06030-3101, USA.
Kevin ClarkCenter for Molecular Oncology, University of Connecticut School of Medicine, Farmington, CT 06030-3101, USA.
Justin BellizziCenter for Molecular Oncology, University of Connecticut School of Medicine, Farmington, CT 06030-3101, USA.
Andrew ArnoldCenter for Molecular Oncology, University of Connecticut School of Medicine, Farmington, CT 06030-3101, USA.
University of Connecticut · US

Funding

Modeling of Hyperparathyroidism-Jaw Tumor Syndrome by Targeted Deletion of Hrpt2F32DE021307 · NIDCR · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI COSTA, JESSICA · 2010 to 2012
$110k
NIDCR NIH HHS F32 DE021307
6 · The paper itself

Abstract

Hyperparathyroidism jaw-tumor syndrome is an autosomal dominant disorder caused by mutations in the

Indexed as

hyperparathyroidismhyperparathyroidism-jaw tumor syndromeparafibrominparathyroid carcinomaparathyroid neoplasia

Identifiers

PMID38328479
PMCPMC10849604
OpenAlexW4391049365

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.